Browse the evidence

GLP-1 medicines may suppress tumorigenesis through various mechanisms.

Further research is needed to understand the mechanisms by which GLP-1 medicines may affect tumorigenesis.

Carbon monoxide (CO) has potential therapeutic applications in obesity treatment.

Practitioners might explore CO-based therapies as innovative options for obesity management.

GLP-1 RAs slow both thoracic and abdominal aneurysm growth.

GLP-1 RAs may be beneficial in managing aneurysms in clinical settings.

Resmetirom is the first drug approved for MASLD, demonstrating histological efficacy in addressing both steatohepatitis and fibrosis.

Practitioners can consider resmetirom as a treatment option for MASLD.

The review discusses the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders.

Understanding the role of metabolic drugs in managing inflammatory comorbidities can enhance treatment strategies.

Metabolic drugs may be repurposed as direct anti-inflammatory agents.

Exploring the repurposing of metabolic drugs could lead to new anti-inflammatory therapies.

The optimized nanocomplex of semaglutide with protamine and zinc exhibited a particle size of 196.0 nm and a zeta potential of -45.7 mV.

The nanocomplex's size and charge may influence its delivery and efficacy.

The nanocomplexes showed markedly delayed release of semaglutide, with only 19% drug release over 7 days.

The delayed release may improve the effectiveness of semaglutide in clinical settings.

Key chemobiological mechanisms implicated in obesity include dysregulated leptin-ghrelin signaling, chronic low-grade inflammation, and altered adipokine profiles.

Understanding these mechanisms can help in developing targeted interventions for obesity.

Advances in understanding molecular causes of rare genetic obesities have led to therapies targeting appetite regulation.

Practitioners should consider new therapies targeting appetite regulation for patients with rare genetic obesities.

Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and bile acid receptors including the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5).

Practitioners should stay informed about these novel molecular targets for potential future therapies in obesity management.

The effects of rifampicin on obesity are mediated through Sirt6.

Targeting Sirt6 may enhance the effectiveness of rifampicin in obesity treatment.

Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.

DACRAs may offer new treatment options for improving insulin sensitivity.

The comparative bioavailability of semaglutide following oral administration (3 mg) relative to subcutaneous administration (0.25 mg) is 0.66%.

Practitioners should note the lower bioavailability of oral semaglutide compared to subcutaneous administration.

The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses.

Understanding the pharmacokinetics can inform dosing strategies for semaglutide.

Molecular engineering strategies have advanced biologic therapies for diabetes by optimizing therapeutic stability, pharmacokinetics, and delivery.

Practitioners can leverage molecular engineering to enhance diabetes therapies.

Structural modifications such as amino acid substitutions and PEGylation enhance stability and extend half-life of diabetes therapeutics.

Incorporating these modifications can improve the efficacy of diabetes treatments.

iWAT injection of MPDA@TZP improved leptin resistance, beiging, lipid metabolism, mitochondrial activity, and branched-chain amino acid (BCAA) catabolism in iWAT.

Understanding these metabolic improvements can guide targeted therapies for obesity.

Defects in mitochondrial oxidative phosphorylation contribute to insulin resistance and β-cell apoptosis.

Addressing mitochondrial oxidative phosphorylation may improve insulin sensitivity.

Research priorities include genetic/epigenetic factors, brain-periphery communication, and environmental influences.

Understanding these factors can guide research and interventions in endocrine health.

There is a biologically plausible link between GLP-1 RAs and pathways central to periodontal inflammation and host response.

Understanding this link may guide future research on periodontal treatments.

The oleogel-in-oleogel system reduces in vitro digestibility by 17%–26% compared to control oleogels and up to 33% compared to single-component oleogels.

This system may help in reducing caloric intake from fats, aiding in obesity management.

The type of outer oleogel affects the digestibility of the oleogel-in-oleogel system.

Choosing the right outer oleogel could optimize the digestibility of fat substitutes.

Inhibiting the Group-specific component (GC) gene may provide a novel therapeutic target for treating metabolic diseases.

Practitioners may consider exploring GC inhibition as a treatment option for metabolic diseases.